We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CV Safety Analysis of New Metabolic Heart Drugs Focus of EMA Guideline
CV Safety Analysis of New Metabolic Heart Drugs Focus of EMA Guideline
Sponsors of new drugs to treat cardiovascular and metabolic diseases should use a composite of all major cardiovascular events as the primary endpoint in studies to establish CV risk, the European Medicines Agency says.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor